<DOC>
	<DOCNO>NCT01464476</DOCNO>
	<brief_summary>This study evaluate efficacy safety Azimilide incidence cardiovascular hospitalization , cardiovascular emergency department visit cardiovascular death patient Implantable Cardioverter Defibrillators ( ICDs )</brief_summary>
	<brief_title>Efficacy Safety Study Azimilide Incidence Cardiovascular Hospitalizations/Emergency Department Visits Cardiovascular Death Patients With Implantable Cardioverter Defibrillator ( ICD ) ( SHIELD-2 )</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Arrhythmias , Cardiac</mesh_term>
	<mesh_term>Azimilide</mesh_term>
	<criteria>Have ICD implant history ventricular tachycardia , ventricular fibrillation , appropriate ICD therapy . Have leave ventricular ejection fraction &lt; = 0.40 Have New York Heart Association ( NYHA ) Class IV Congestive Heart Failure ( CHF ) decompensated CHF time randomization ; Have unstable angina pectoris myocardial infarction within 30 day randomization ; Have history Torsade de Pointes heart transplantation Have chronic atrial fibrillation atrial fibrillation/flutter , adequately rate control judgment Investigator , screening ; Are currently take systemic Class I Class III antiarrhythmic drug Are currently take systemic drug prolong QT interval If female , currently pregnant breast feeding , plan become pregnant course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>